प्राथमिक स्रोत रिकॉर्ड
निर्णायकआवेदन जमा
Teva ने Tourette syndrome में ecopipam (EBS-101) के लिए NDA दाखिल किया
Teva submitted a New Drug Application to the U.S. FDA in June 2026 for ecopipam (EBS-101), a first-in-class therapy for Tourette syndrome, following the $700 million acquisition of Emalex Biosciences. The NDA submission advances the asset from pre-submission to active regulatory review, marking a key regulatory milestone for Teva's neuroscience pipeline.
मुख्य तथ्य
स्रोत का अंश
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in LC, to over $1 billion in revenues, and we raised our 2026 outlook for all three, highlighting Teva’s continued execution of its Pivot to Growth strategy. Key Innovative brands continued to drive growth while transforming Teva’s portfolio mix and financial profile: AUSTEDO ® continued to grow rapidly, with global revenues of $696 million, growing 40% YoY in LC